Currently, between 20% and 75% of patients respond to a particular therapy, depending on the type of cancer and indication.
Bayer recognizes that the ability to identify responders or non-responders to its compounds in development will greatly advance treatment options for patients in the future.
Therefore, Bayer´s objective is to develop a biomarker strategy for each oncological compound in development before it enters clinical trials.
Thus, every oncology compound is evaluated to determine its potential for a patient stratification approach.
Personalized approaches using patient stratification
To detect the differences between patients, established stratification markers, also known as biomarkers, are used or new biomarkers are explored.
In its search for suitable biomarkers, Bayer investigates the molecular characteristics of tumors.
Innovative technology platforms are used to assess the entire pathway of a particular tumor type, or to focus on the genetic make up of the tumor.
The molecular basis of the tumor is then used to determine which patients are more likely to respond, i.e. patient stratification.
Bayer has also initiated research to detect tumor-specific markers in blood, which could have the potential to reduce the need for tumor biopsies.
Access to diagnostic expertise through external partners
Driven by specific project needs and in line with Bayer´s personalized medicine strategy, partnerships are undertaken to ensure access to state-of-the-art diagnostic expertise.
Bayer´s flexible partnering strategy is a key to successful delivery of personalized medicine.
Bayer recognizes that its commitment to biomarker research will open the door to personalized medicine that´ll benefit cancer patients. It will help us to fully leverage the opportunities of personalized medicine wherever the scientific rationale is given.